Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Tamara Ghanem

- PMLiVE

Halozyme faces late-stage pancreatic cancer drug failure, cuts 55% of jobs

Will now focus on its novel drug delivery platform to drive business growth

Lucid Group celebrates a fang-tastic Halloween

Last week the Lucid charity working group, Lucid SPIRIT, organised a fang-tastic Halloween Bingo evening to raise money for its charity partner, Wycombe Homeless Connection (WHC).Lucidians went to town with...

Lucid Group Communications Limited

- PMLiVE

Sanofi reveals positive phase 3 results for long-acting insulin Toujeo

Hopes new product can offset continuing decline in franchise

- PMLiVE

MD Anderson exec Stephen Hahn to be nominated FDA commissioner

US President Trump scouts well-known oncology expert to lead agency

- PMLiVE

China okays Green Valley’s algae-based drug for Alzheimer’s drug

Due to start phase 3 trials in the US and Europe next year

- PMLiVE

OPEN Health announces the integration of Pharmerit International into the group

OPEN Health has today announced the integration of Pharmerit International, a global leader in health economics and outcomes research (HEOR), into its group of companies.

OPEN Health

- PMLiVE

Sanofi settles Lemtrada dispute with Genzyme investors for $315m

The MS drug has been in decline amid increased market competition

Article: Market access in Brazil

All eyes on Spinraza

Inizio

China: How to strategise and win in the world’s fastest changing healthcare market

In this paper, experts Marc Yates, Pei Li Teh and Brett Gardiner discuss the China healthcare reforms which affect pharma and propose how to build the market understanding required to launch...

Inizio

Infographic: Preparing to launch a new asset and in need of demand assessment research?

Download our pre-launch checklist

Inizio

How ready are you for launch?

Pharmaceutical launches are becoming more complex and competitive. Our launch excellence diagnostic tool helps you to map how ready you are for launch, while facilitating success in this challenging environment.

Blue Latitude Health

Novartis building

Novartis’ Cosentyx misses the mark in Humira head-to-head

Narrowly missed statistical significance for superiority

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links